Navigation Links
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
Date:4/21/2009

_new">www.aacr.org. A copy of the posters presented at AACR may be obtained by contacting the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. We are developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. We are also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company is also engaged in business development activities that include evaluating compounds and companies for in-licensing or acquisition, as well as seeking strategic relationships for our product candidates and for our company. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014 TransVac Solutions, the trusted leader ... transport solutions for hospitals, will be exhibiting at booth ... Annual Conference & Technical Exhibition Aug. 3-6 in Chicago, ... for making hospitals cleaner, reducing infection risk and saving ... life cycle. Staff will be available at booth ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)... 29, 2014 G-CON Manufacturing Inc., the ... today announced a new leadership appointment designed to drive ... and abroad. , Maik Jornitz, Chief Operating Officer ... President charged with leading the pioneering company through its ... this stage of development and look forward to providing ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... May 22 Advance Nanotech, Inc., (OTC,Bulletin Board: AVNA), ... selected as one of four finalists for the 2008 ... for,innovation in engineering. HRH the Duke of Edinburgh will ... medal to the winner of this year,s,competition at the ...
... Inc. (Nasdaq and SWX: BMRN) will host a ... Thursday, June 5, 2008 from,7:30 a.m. to 11:30 ... New York City. Members,of BioMarin,s senior management team ... new information about advancements in the,research and development ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... REOLYSIN(R) at the 40-litre,batch size to SAFC ... the successful scale-up from 20 litres to ... Yields at the 40-litre scale should ...
Cached Biology Technology:Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 2Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 3Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 4BioMarin to Host Research and Development Day June 5th 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3
(Date:7/29/2014)... Maryland Schools of Dentistry (UM SOD) and Medicine ... received a five-year $10.7 million grant award from ... (NIAID) of the National Institutes of Health to ... diseases (STDs). The grant, which renews a previous ... new direction for the research by studying chlamydial ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
... with Sartorius Stedim Biotech (SSB) and Adolf Kühner AG ... 2009 , ,Monthey, 19. Mai 2009 / b3c ... contract manufacturing to the biopharmaceutical industry, expands its product ... bioreactor. OrbShake bioreactors rely on orbital shaking ...
... plants into a renewable, nonpolluting replacement for crude oil. ... convert plant biomass into a building block for plastics ... have successfully converted cellulose -- the most common plant ... in one step. The result builds upon ...
... recently awarded 13 grants totaling more than $191,000 ... Grant proposals were reviewed during SIR,s 34th Annual ... Foundation is proud to be able to contribute ... SIR Foundation grant program is designed to benefit ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3Plastic that grows on trees, part two 2Society of Interventional Radiology Foundation awards $191,000 in grants 2Society of Interventional Radiology Foundation awards $191,000 in grants 3